GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All conditions

GLP-1 Therapy for Sleep Apnea (OSA) in India — Evidence

Last reviewed 12 May 2026 · Indian guideline context

The short answer

GLP-1 therapy — particularly tirzepatide (Mounjaro) — shows strong evidence for improving obstructive sleep apnea (OSA) in patients with obesity. The SURMOUNT-OSA trial demonstrated up to 50% reduction in apnea-hypopnea index with tirzepatide. In India, GLP-1 is prescribed for OSA + obesity under the obesity indication (BMI ≥27.5 or ≥25 with comorbidities). Take the 5-min eligibility check.

See if you’re a candidate

The 5-minute Indian-guideline eligibility check factors in your Obstructive Sleep Apnea status.

Take the free assessment →

Obstructive Sleep Apnea in India — the context

Obstructive sleep apnea (OSA) is significantly under-diagnosed in India — estimated 13.7% prevalence in adults, with much higher rates (25-35%) in obese populations. Diagnosis requires polysomnography (sleep study), available at major hospital networks in Delhi NCR, Mumbai, Pune, Bangalore, Chennai, and increasingly Hyderabad and Jaipur. Indian patients often present with severe OSA at lower BMI than Western populations due to craniofacial anatomy differences. CPAP adherence in India is challenged by cost, equipment maintenance, and lifestyle factors — making weight-loss-driven OSA improvement particularly valuable.

How GLP-1 helps — mechanism + evidence

GLP-1 receptor agonists improve OSA primarily through weight loss — reduction in upper airway adiposity and improved respiratory mechanics. Secondary mechanisms may include direct effects on respiratory drive and inflammation. The SURMOUNT-OSA Phase 3 trial (tirzepatide) showed apnea-hypopnea index (AHI) reductions of 27-30 events/hour at 52 weeks — among the largest treatment effects ever recorded in OSA pharmacotherapy. FDA approval for tirzepatide in OSA followed in late 2024 / early 2025; DCGI label expansion in India is pending.

Key trials

  • SURMOUNT-OSA: Tirzepatide 15 mg reduced apnea-hypopnea index by 27.4 events/hour at 52 weeks vs 4.8 events/hour placebo — approximately 50% AHI reduction in obese OSA patients.
  • STEP 1: Semaglutide 2.4 mg achieved 15% weight loss in obese patients; OSA subgroup analyses showed meaningful AHI improvements.
  • SCALE Sleep Apnea (liraglutide): Liraglutide 3 mg in obese OSA patients reduced AHI by 12.2 events/hour at 32 weeks vs 6.1 placebo.
  • SURMOUNT-1: Tirzepatide 15 mg achieved 22.5% weight loss at 72 weeks; OSA-comorbid subgroup analyses showed substantial respiratory improvement.

Eligibility — who fits?

GLP-1 for OSA + obesity in India is prescribed under the obesity indication (BMI ≥27.5 or ≥25 with comorbidities). A formal sleep study (polysomnography) is required to document OSA severity (AHI). The 5-min GLP-1 Check assessment factors in BMI, OSA severity, current CPAP use, and comorbidities. Patients with severe OSA (AHI ≥30) typically need CPAP alongside GLP-1 initially; CPAP may be tapered as weight drops and AHI improves.

Indian-context considerations

  • •Polysomnography (sleep study) is required for OSA diagnosis — most Indian metros have sleep labs at major hospitals (AIIMS, Max, Fortis, Apollo, KEM, etc.); home sleep tests are increasingly available
  • •CPAP adherence remains the cornerstone of severe OSA management — GLP-1 does not replace CPAP, but supports weight-driven AHI reduction that may eventually allow CPAP reduction or discontinuation
  • •Indian patients often have craniofacial features (smaller maxilla, larger soft palate) that contribute to OSA independent of weight — weight loss alone may not fully resolve OSA in these cases
  • •Excessive daytime sleepiness from OSA can worsen during early GLP-1 titration due to caloric reduction; ensure adequate hydration and discuss any worsening symptoms with your physician
  • •Tirzepatide (Mounjaro) is the strongest evidence-based choice for obesity + OSA, given SURMOUNT-OSA outcomes; semaglutide and liraglutide are also reasonable options

Brand options for Obstructive Sleep Apnea

Mounjaro

Strongest evidence (SURMOUNT-OSA) for OSA-specific improvement. FDA-approved for OSA in late 2024 / early 2025; DCGI label expansion pending. Best choice when OSA is a primary management target.

Wegovy

On-label for obesity. STEP and SCALE Sleep Apnea evidence supports OSA improvement through weight loss.

Indian generic semaglutide

For cost-conscious patients where Wegovy is not affordable. Same active molecule as Wegovy; clinical benefit follows weight loss outcomes.

Full brand catalog: Semaglutide brands in India → · India pricing →

Patient pathway

Typical OSA + obesity pathway: (1) polysomnography (sleep study) for OSA diagnosis and severity — most Indian metros have hospital-based sleep labs; (2) pulmonology or sleep-medicine consult; (3) endocrinology consult for GLP-1 prescribing under the obesity indication; (4) baseline labs and BMI assessment; (5) initiate CPAP for severe OSA (AHI ≥30); (6) start GLP-1 titration; (7) reassess OSA severity with repeat sleep study at 6-12 months — many patients can taper CPAP as weight drops.

Frequently asked questions

Will GLP-1 cure my sleep apnea?+
For obesity-driven OSA, yes — often substantially. The SURMOUNT-OSA trial showed ~50% reduction in AHI with tirzepatide 15 mg at 52 weeks. Many patients move from severe (AHI ≥30) to moderate (15-29) or mild (5-14) OSA after sustained weight loss + GLP-1 therapy. Anatomical OSA (driven by craniofacial features) may require additional interventions.
Can I stop CPAP if I take GLP-1?+
Not initially. CPAP should continue throughout GLP-1 titration. After 6-12 months of therapy and substantial weight loss, repeat polysomnography may show improved AHI — at which point CPAP can be reduced or tapered under your sleep-medicine specialist's guidance. Never stop CPAP without medical guidance, especially with severe OSA.
Is Mounjaro approved for sleep apnea in India?+
Not yet — the FDA approved tirzepatide for moderate-to-severe OSA in patients with obesity in late 2024 / early 2025. DCGI label expansion in India is pending. Current Indian prescribing for OSA + obesity is under the obesity indication, with OSA noted as a comorbidity driving the decision to use tirzepatide specifically.
How is sleep apnea diagnosed in India?+
Polysomnography (overnight sleep study) is the gold standard. Most Indian metros have sleep labs at major hospitals — AIIMS, Max, Fortis, Apollo, KEM, BLK, Medanta, and similar networks. Home sleep tests (HST) are increasingly available for moderate-severe OSA. Cost: in-lab polysomnography typically ₹6,000–15,000; home tests ₹3,000–6,000.
I have OSA but my BMI is below 27.5 — can I still take GLP-1?+
Indian-guideline GLP-1 prescribing requires BMI ≥27.5 (or ≥25 with comorbidities). OSA qualifies as a comorbidity at BMI ≥25, so many OSA patients are eligible under the obesity indication. For BMI <25 OSA patients, GLP-1 is not first-line — focus on CPAP, oral appliances, positional therapy, and addressing other contributors.
How long until my OSA improves on GLP-1?+
AHI improvements typically follow weight loss, which usually starts in week 4-8 of titration. Meaningful OSA improvement is generally seen at 3-6 months, with maximal effect at 12-18 months. SURMOUNT-OSA showed AHI improvements building progressively over 52 weeks of tirzepatide therapy.
Will my snoring stop with GLP-1?+
Often — though snoring reduction follows weight loss + airway-tissue reduction rather than direct GLP-1 effect. Many patients (and their partners) notice snoring reduction within 3-6 months of starting therapy. Persistent snoring despite weight loss may suggest anatomic factors needing ENT evaluation.

Related conditions

Type 2 Diabetes

GLP-1 for Type 2 Diabetes — Indian context

Hypertension

GLP-1 for Hypertension — Indian context

Fatty Liver (NAFLD/MASLD)

GLP-1 for Fatty Liver (NAFLD/MASLD) — Indian context

See if GLP-1 fits your Obstructive Sleep Apnea profile

5 minutes. Uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Take the free assessment →

Educational content based on DCGI-approved labelling, peer-reviewed trials, RSSDI/ESI/INASL Indian clinical guidelines, and published literature. Not a substitute for a doctor’s clinical judgment. GLP-1 therapies are Schedule H drugs in India and require a doctor’s prescription. Always consult a qualified medical practitioner before starting any therapy.